Chapter 1 : Igor B Roninson

Treatment-induced senescence, which has both similarities with, and differences from, replicative senescence of normal cells, was shown to be one of the key determinants of tumor response to therapy in vitro and in vivo.

The foregoing techniques and procedures may be generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. New York, which is incorporated herein by reference for any purpose. Unless specific definitions are provided, the nomenclature utilized in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques may be used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients. Cell growth is determined by comparing the number of cells cultured in the presence and absence of the agent and detecting growth inhibition when there are fewer cells in the presence of the agent than in the absence of the agent after an equivalent culture period of time. Examples of such cytotoxic agents include but are not limited to doxorubicin, aphidicolin, cisplatin, cytarabine, etoposide, taxol, ionizing radiation, retinoids or butyrates. Appropriate dosages will vary with different cell types; the determination of the dose that induces senescence is within the skill of one having ordinary skill in the art, as disclosed in Chang et al. Such cell death is frequently but not always preceded by the formation of micronucleated interphase cells, which are thus an indicator of mitotic catastrophe. In addition, mitotic catastrophe may also lead to apoptosis. Mitotic catastrophe can be conveniently induced in mammalian cells by contacting the cells with a cytotoxic agent as disclosed in Chang et al. Mitotic catastrophe can be determined microscopically by observing mitotic figures that are clearly different from normal, as illustrated in FIG. Examples of cytotoxic agents effective for inducing mitotic catastrophe include but are not limited to doxorubicin, aphidicolin, cisplatin, cytarabine, etoposide, ionizing radiation, taxol or Vinca alkaloids. Appropriate dosages will vary with different cell types; the determination of the dose that induces mitotic catastrophe is within the skill of one having ordinary skill in the art, as disclosed in Chang et al. This analysis was expanded to a panel of 14 solid tumor-derived cell lines that were treated with moderate equitoxic doses of doxorubicin. Only two lines showed predominantly apoptotic response, whereas all the other lines developed mitotic catastrophe, with or without apoptosis. Eleven of 14 lines also exhibited the senescent phenotype after doxorubicin treatment. P-glycoprotein protected two apoptosis-prone cell lines from radiation-induced apoptosis, but it did not increase the clonogenic survival of radiation. This apparent paradox was resolved by finding that a decrease in the fraction of apoptotic cells was accompanied by a commensurate increase in the fraction of cells undergoing either senescence or mitotic catastrophe, indicating that the latter responses, without apoptosis, are sufficient to stop proliferation of tumor cells. The latter responses, however, are not only common in cancer treatment but also possess certain advantages over apoptosis as cancer treatment strategies. Cells that undergo senescence do not divide but remain metabolically and synthetically active and produce secreted factors with important paracrine activities. While some of these factors may promote tumor growth by inhibiting apoptosis or by acting as mitogens, other factors such as maspin, IGF-binding proteins or amphiregulin have the opposite, tumor-suppressive effect as disclosed in co-owned and co-pending U. Some inducers of senescence, such as retinoids, stimulate the production of tumor-suppressive but not of tumor-promoting proteins as disclosed in co-owned and co-pending U. In contrast to senescence, apoptotic cells rapidly die and disappear, and therefore do not produce any factors that may suppress the growth of tumor cells that had escaped lethal damage. Apoptosis is a physiological anti-carcinogenic program of normal cells. In the course of carcinogenesis, tumor cells develop various

changes that suppress apoptotic programs, such as mutational inactivation of p53 and upregulation of BCL-2 an inhibitor of apoptosis. As a result, many tumor cells show diminished apoptotic response as disclosed in co-owned and co-pending U. In contrast, mitotic catastrophe is not a physiological program but rather a consequence of direct interference with mitosis the effect of anti-mitotic drugs, such as Vinca alkaloids or taxanes , or of the entry of cells, damaged at interphase, into mitosis. The latter situation occurs when cells treated with DNA-damaging agents or other drugs that act at interphase enter mitosis after exposure to the drug; abnormal mitosis can also occur after cell cycle perturbation without DNA damage, e. Normal cells possess a variety of cell cycle checkpoint mechanisms that prevent the entry of damaged cells into mitosis. These include, among others, DNA damage-inducible checkpoints that arrest cells in either G1 or G2 phases of the cell cycle, and the prophase checkpoint activated by microtubule-targeting drugs. Checkpoint arrest gives cells time to repair cellular damage, particularly chromosomal DNA damage, and reduces the danger of abnormal mitosis. Tumor cells, however, are almost always deficient in one or more of the cell cycle checkpoints. Inactivation of these checkpoints promotes mitotic catastrophe after treatment with anticancer drugs or radiation. Other advantages of mitotic catastrophe in clinical situations are that i mitotic catastrophe occurs at lower drug doses and therefore under the conditions of lower systemic toxicity than apoptosis Tounekti et al. Doxorubicin induced senescence to a similar extent in both cell lines and showed relatively weak induction of apoptosis. This finding demonstrates that mitotic catastrophe, rather than senescence or apoptosis is the key determinant of tumor specificity of this important, clinically-useful anticancer drug. This finding, together with the above-discussed role of checkpoint deficiencies of tumor cells in promoting mitotic catastrophe, demonstrates that mitotic catastrophe is a tumor-specific mechanism of cell death. Hence, compounds that induce mitotic catastrophe in cancer cells are likely to have a tumor-specific effect, that is, to induce mitotic catastrophe and cell death in cancer cells but not in non-cancer cells. Such compounds can be identified by microscopic assays for abnormal mitotic figures or interphase cells having two or more micronuclei, a common endpoint of mitotic catastrophe. The tumor specificity of such compounds can then be verified by determining that the compounds do not induce or only weakly induce cell death in non-cancer cells. Cell death can be monitored by any standard procedure, such as detecting the appearance of apoptotic cells, or interphase cells with two or more micronuclei, or floating cells, or cells permeable to a dye that does not penetrate live cells such as trypan blue. Screening synthetic or natural compound libraries for agents that induce mitotic catastrophe or senescence is based on measuring the fraction of mitotic cells mitotic index, MI in a cell culture after treatment with a tested compound. MI measurement has been previously used as the basis of screening for drugs that induce mitotic arrest. Such anti-mitotic drugs slow down or block mitosis, resulting in a strong increase in MI. Increased MI has been used in the art to screen for novel anti-mitotic drugs Mayer et al. Another type of mitosis-based screening assays is aimed at identifying agents such as caffeine or UCN that override the G2 checkpoint; such agents can be identified by their ability to prevent the decrease in MI of nocodazole-treated cells after the infliction of DNA damage Roberge et al. Both classes of the latter agents induce cell cycle arrest in the interphase rather than at mitosis and therefore decrease rather than increase the MI. The measurement of MI in the presence of such agents can therefore be used as the first step of screening for both classes of agents. An increase in MI will indicate potential anti-mitotic drugs as in previously described assays , whereas a decrease in MI provides a novel criterion for identifying interphase-acting cell cycle inhibiting agents. Senescence-inducing agents will not permit full recovery of MI after release from the compound. In contrast, agents that induce mitotic catastrophe will not only permit recovery of MI but are likely to produce an increase in MI relative to control cells, since abnormal mitosis is expected to take longer than normal mitosis. For example, Mikhailov et al. The extent of MI recovery after release from the compound will therefore identify compounds that induce either senescence or mitotic catastrophe. The effects of such compounds can then be verified by conventional assays for these two

responses as set forth in Table 1. This screening strategy is schematically illustrated in FIG. In the first step, tumor cells are incubated in the presence of a test compound and the mitotic index MI measured. The time of incubation should be long enough to produce a significant change in the fraction of cells entering mitosis; it may be as short as hours a typical duration of the G2 phase or as long as the duration of the entire cell cycle between 20 hr and 45 hr for most tumor cell lines or longer. Compounds showing increased MI are identified as potential antimitotic agents, which can then be tested for antimitotic activity using methods well known in the art. Compounds in whose presence cells show decreased MI are identified as interphase-acting cell cycle inhibitors and are used in the second step of the assay. Typically, this amount of time is also identified in step 1 of the inventive methods. Thereafter, the cells are released from test compound treatment, for example, by growth in culture media lacking the test compound. The length of time for test compound-free cell growth should be sufficient to allow the cells to re-enter the cycle, and is typically permitted from between 1 and 5 days. The MI of the cells during this time is determined. This result suggests that some of the treated cells have become stably growth-arrested, which is likely to reflect that they have become senescent. As shown herein FIGS. In this case, the cells are assayed for mitotic catastrophe, for example, by microscopic examination of the cells to detect abnormal mitotic figures or micronuclei, or using any appropriate assay for mitotic catastrophe as set forth by illustration herein. Increased mitotic catastrophe in transformed cells was associated not only with a higher rate of mitosis after drug treatment but also with a higher frequency of abnormal relative to normal mitoses. These findings confirmed that the ability to induce mitotic catastrophe provides a basis for tumor cell specificity of a clinically useful anticancer agent. The ability to induce mitotic catastrophe in tumor cells can thus be used to identify tumor-specific cytotoxic compounds that are likely to be useful as anticancer drugs. Methods for screening agents that induce mitotic catastrophe are thus provided by the present invention. Tumor cells are plated in multi-well plates and exposed to test compounds for a period of time sufficient to induce growth arrest if the compounds are capable of growth inhibition , e. Plates are stained with a mitosis-specific antibody, such as MPM2, TG3 or GF7, and antibody binding is detected, for example by indirect immunofluorescence labeling, advantageously using a fluorescence plate reader. Compounds that decrease MI according to this assay are identified and used for further screening in step 3. Compounds that increase MI according to this assay are also identified and used for further screening in step 5. Following treatment with the compounds that are identified in step 2 as decreasing MI, cells are allowed to recover for period s of time sufficient to allow compound-inhibited cells to re-enter the cell cycle typically, 24 hrs, 36 hrs, and 48 hrs [] 4. Plates from step 3 are used to measure MI as described in step 2. Compounds that produce an increase in MI similar to or higher than in untreated cells grown to the same density are identified as potential inducers of mitotic catastrophe. Compounds that produce no increase in MI or a weak increase less than MI of untreated cells grown to the same density are also identified as potential inducers of senescence. Compounds identified in step 2 or step 4 by an increase in MI are added to cells, and mitotic figure morphology during and after treatment with the compound and whether micronuclei are present is analyzed by microscopic assays. Such scoring can be done on unfixed cells using phase contrast microscopy , or by bright-field microscopy after staining cells with any convenient dye that differentially stains nuclei e. In identifying micronucleated cells as end points of mitotic catastrophe, it is important to distinguish them from apoptotic cells which may result either from mitotic catastrophe or from mitosis-independent apoptosis. While apoptotic cells also have fragmented nuclei, they can be distinguished by small size and shrunken cytoplasm, whereas micronucleated cells are large and have normal-size cytoplasm. Furthermore, staining with DNA-specific dyes shows that apoptotic cells have condensed chromatin, whereas micronucleated cells are interphase cells having decondensed chromatin that arise after abnormal mitosis. Micronucleated cells may have two or more completely or partially separated nuclei; in the case of partial separation, the nuclei appear multilobulated. Representative examples of abnormal nuclear morphology that results from mitotic

catastrophe in HT fibrosarcoma cells are shown in FIG. Another method for detecting micronuclei relies on the use of fluorescence-activated cell sorting FACS , as described for example in Torres and Horwitz , Cancer Res. Whereas micronucleation represents an end point of mitotic catastrophe, the process of abnormal mitosis can also be readily identified by microscopic analysis of cells stained with a DNA-specific detection reagent such as a dye for example, DAPI using standard procedures see, for example, Freshney, , Id. Preferred procedures also include cells transfected with an expression vector for histone H2B-GFP fusion protein, which permits visualization of mitotic figures by fluorescence microscopy of intact cells, without any fixation or staining procedures as disclosed in Kanda et al. Exemplarily, for this analysis, cells are cultured in media free of phenol red that provides some background fluorescence. Cells are examined using an inverted fluorescence microscope and mitotic figures photographed, to collect a sufficient number typically, about of mitotic images per sample. These mitotic figures are examined and classified with regard to the type of normal or abnormal mitoses that they represent, using the classification of mitotic figures in Therman and Kuhn , Crit Rev. Another indication of abnormal mitosis is altered frequency distribution of different phases of mitosis. Characteristically, drug-induced abnormal mitoses are characterized by a lower frequency of anaphases and telophases, as well as abnormal morphology. In a particular example of this type of analysis, fluorescence video microscopy of HT cells expressing histone H2B-GFP fusion protein can be used as illustrated in an online supplement to the Science review of Rieder and Khodjakov, , Science Media containing the test compound in 1. Plates are periodically examined for the reappearance of mitotic figures. Once mitoses begin to appear, the cover slip is transferred into a chamber of the incubator system for use with an inverted fluorescence microscope equipped with a heated stage. The microscope is connected to a digital time-lapse camera synchronized with an automatic shutter that allows fluorescent illumination only at the time of taking images. The images are collected intermittently, for example, using a 3-minute periodicity.

Chapter 2 : - NLM Catalog Result

Treatment-induced senescence and mitotic catastrophe in tumor cells Author links open overlay panel Igor B. Roninson f1 Eugenia V. Broude Bey-Dih Chang Show more.

Chapter 3 : Screening strategy for anticancer drugs - BROUDE EUGENIA

Get this from a library! Beyond apoptosis: cellular outcomes of cancer therapy. [Igor B Roninson; J M Brown; Dale E Bredesen;] -- Apoptosis, the process of deliberate cell death within a multi-cellular organism, has been linked to both the development and the demise of cancer causing cells.

Chapter 4 : Publications Authored by Michael Shtutman | PubFacts

Treatment-induced senescence, which has both similarities with, and differences from, replicative senescence of normal cells, was shown to be one of the key determinants of tumor response to.

Chapter 5 : Publications Authored by Igor B Roninson | PubFacts

Inhibition of the program of apoptosis has been reported to have little or no effect on clonogenic survival after treatment with drugs or radiation in several tumor cell lines.